Improve walking with transcranial stimulation
- Trial ID
- NCT07291687
- Official Title
- Transcranial Direct Current Stimulation as a Treatment for Motor Function in Participants Living With Progressive Supranuclear Palsy, Corticalbasal Syndrome Degeneration, or Parkinson's Disease
- Goal
- Improve walking with transcranial stimulation
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Baycrest
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Progressive Supranuclear Palsy, Cortical Basal Ganglionic Degeneration, Parkinson Disease
- Interventions
- Transcranial direct current stimulation (TDCS), Stimulation Arm
Plain-Language Summary
The trial is testing whether mild electrical brain stimulation can improve walking and other motor problems in people with progressive supranuclear palsy, corticobasal degeneration, or Parkinson's disease. It uses transcranial direct current stimulation, a low-intensity current applied to the scalp that changes cortical excitability to strengthen motor circuits; because it is a non-drug intervention it does not alter how levodopa is metabolized and can be given alongside usual Parkinson's meds. The study is looking for adults with one of those diagnoses who walk daily, either unaided or with a cane or walker, who can communicate in English, and who do not have metal implants in the brain such as shunts.
Locations
- Baycrest Academy of Health Sciences and Geriatric Research, Toronto, Ontario, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Transcranial direct current stimulation (TDCS). The trial is testing whether mild electrical brain stimulation can improve walking and other motor problems in people with progressive supranuclear palsy, corticobasal degeneration, or Parkinson's disease. It uses transcranial direct current stimulation, a low-intensity current applied to the scalp that changes cortical excitability to strengthen motor circuits; because it is a non-drug intervention it does not alter how levodopa is metabolized and can be given alongside usual Parkinson's meds. The study is looking for adults with one of those diagnoses who walk daily, either unaided or with a cane or walker, who can communicate in English, and who do not have metal implants in the brain such as shunts.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 1 month.